Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects

References

• Abad MJ, Bedoya LM, Bermejo P. (2010). An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab 11:171–81
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Dole K, He YL, et al. (2007). Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 23:2913–20
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A; Cholesterol Treatment Trialists’ (CTT) Collaborators, et al. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–78
   Google Scholar
• Barrett B, Huclová J, Borek-Dohalský V, et al. (2006). Validated HPLC-MS/MS method for simultaneous determination of simvastatin and simvastatin hydroxy acid in human plasma. J Pharm Biomed Anal 41:517–26
   PubMed Web of Science ®Google Scholar
• Chang TK. (2009). Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J 11:590–601
   PubMed Web of Science ®Google Scholar
• Chen C, Mireles RJ, Campbell SD, et al. (2005). Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537–46
   PubMed Web of Science ®Google Scholar
• Eckert GP, Hooff GP, Strandjord DM, et al. (2009). Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered male Alzheimer patients. Neurobiol Dis 35:251–7
   PubMed Web of Science ®Google Scholar
• Elsby R, Hilgendorf C, Fenner K. (2012). Understanding the critical disposition pathways of statins to assess drug--drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther 92:584–98
   PubMed Web of Science ®Google Scholar
• Etheridge AS, Black SR, Patel PR, et al. (2007). An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73:731–41
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL; NIAID AIDS Clinical Trials Group, et al. (2002). Pharmacokinetic interactions between protease inhibitors and statins in seronegative volunteers: ACTG Study A5047. AIDS 16:569–77
   Google Scholar
• Guo CX, Pei Q, Yin JY, et al. (2012). Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica. 42:784–90
   PubMed Web of Science ®Google Scholar
• Jacobson TA. (2004). Comparative interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140–6
   PubMed Web of Science ®Google Scholar
• Joshi BS, Kaul PN. (2001). Alternative medicine: herbal drugs and their critical appraisal – part I. Prog Drug Res 56:1–76
   PubMedGoogle Scholar
• Krishna R, Garg A, Jin B, et al. (2009). Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 67:520–6
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivistö KT, et al. (2000). Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68:592–7
   PubMed Web of Science ®Google Scholar
• Lau AJ, Yang G, Rajaraman G, et al. (2010). Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J Pharmacol Exp Ther 335:771–80
   PubMed Web of Science ®Google Scholar
• Li L, Stanton JD, Tolson AH, et al. (2009). Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 26:872–82
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Kivistö KT, Neuvonen PJ. (1998). Grapefruit simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477–83
   PubMed Web of Science ®Google Scholar
• Liu BQ, Zhang L, Yang QD, et al. (2008). The association of apolipoprotein B gene polymorphism with cerebral infarction with positive family history and its effect on plasma lipid levels. Zhonghua Yi Xue Za Zhi. 88:3332–6
   PubMedGoogle Scholar
• Liu R, Li F, Liang R, et al. (2009). Influence of gingko extract on metabolism of simvastatin. Zhongguo Zhong Yao Za Zhi 34:1578–81
   PubMedGoogle Scholar
• Luo G, Cunningham M, Kim S, et al. (2002). CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795–804
   PubMed Web of Science ®Google Scholar
• Mandery K, Balk B, Bujok K, et al. (2012). Inhibition of hepatic uptake transporters by flavonoids. Eur J Pharm Sci 46:79–85
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, Lindsay DeVane C, et al. (2003). Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 23:576–81
   PubMed Web of Science ®Google Scholar
• Moore LB, Goodwin B, Jones SA, et al. (2000). St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–2
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. (2010). Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 11:323–32
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–81
   PubMed Web of Science ®Google Scholar
• Oscarson M, Zanger UM, Rifki OF, et al. (2006). Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 80:440–56
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873–9
   PubMed Web of Science ®Google Scholar
• Pei Q, Huang Q, Yang GP, et al. (2013). PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China. Acta Pharmacol Sin 34:255--61
   Google Scholar
• Prueksaritanont T, Ma B, Yu N. (2003). The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56:120–4
   PubMed Web of Science ®Google Scholar
• Robertson SM, Davey RT, Voell J, et al. (2008). Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24:591–9
   PubMed Web of Science ®Google Scholar
• Senn S. (2002). Cross-over trials in clinical research. 2nd ed. Chichester, West Sussex, England: John Wiley & Sons, Ltd
   Google Scholar
• Sugimoto K, Ohmori M, Tsuruoka S, et al. (2001). Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70:518–24
   PubMed Web of Science ®Google Scholar
• Sunkara G, Reynolds CV, Pommier F, et al. (2007). Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Curr Med Res Opin 23:631–40
   PubMed Web of Science ®Google Scholar
• Ucar M, Neuvonen M, Luurila H, et al. (2004). Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59:879–82
   PubMed Web of Science ®Google Scholar
• Wu LX, Guo CX, Chen WQ, et al. (2012a). Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. Br J Clin Pharmacol 73:750–7
   PubMed Web of Science ®Google Scholar
• Wu LX, Guo CX, Qu Q, et al. (2012b). Effects of natural products on the function of human organic anion transporting polypeptide 1B1. Xenobiotica 42:339–48
   PubMed Web of Science ®Google Scholar
• Yeung EY, Sueyoshi T, Negishi M, Chang TK. (2008). Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 36:2270–6
   PubMed Web of Science ®Google Scholar
• Zadoyan G, Rokitta D, Klement S, et al. (2012). Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction studying healthy volunteers. Eur J Clin Pharmacol 68:553–60
   PubMed Web of Science ®Google Scholar
• Zheng XE, Wang Z, Liao MZ, et al. (2012). Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D3 function in human colon adenocarcinoma LS180 cells. Biochem Pharmacol 84:391–401
   PubMed Web of Science ®Google Scholar
• Zocor®. (2011). Summary of product characteristics (March 2011). Available from: http://www.medicines.org.uk/EMC/medicine/1201/SPC/Zocor+10mg%2c+20mg%2c+40mg++and+80mg+film-coated+tablets/ [last accessed 4 Oct 2011]
   Google Scholar
• Zuo XC, Zhang BK, Jia SJ, et al. (2010). Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 66:503–9
   PubMed Web of Science ®Google Scholar